Table 2.
Results of tests of association at rs372271081 for survival without BPD using logistic regression and urinary NO metabolites following iNO treatment using linear regression
| Survival without BPD |
Urinary NO Metabolites |
|||||||
|---|---|---|---|---|---|---|---|---|
| Population | Frequency in Cases, n | Frequency in Controls, n | Odds Ratio | P Value | n | β (SE) | 95% CI | P Value |
| Non-Hispanic white | 0.040 (136) | 0.12 (41) | 0.30 | 6.2 × 10−3 | 26 | −5.3 (1.7) | (−8.7, −1.9) | 6.2 × 10−3 |
| African American | 0.055 (82) | 0.19 (51) | 0.25 | 6.9 × 10−4 | 23 | 0.74 (2.3) | (−3.8, 5.2) | 0.75 |
| Hispanic white | 0.018 (28) | 0.11 (14) | 0.15 | 0.070 | 13 | −1.9 (2.3) | (−6.5, 2.7) | 0.45 |
Results are shown with respect to the minor allele (A), which trends as protective for bronchopulmonary dysplasia (BPD) in 3 populations and is significantly associated with lower urinary NO metabolites in infants of maternal non-Hispanic white race/ethnicity. β, Regression coefficient/effect size; CI, confidence interval; iNO, inhaled nitric oxide; SE, standard error.